Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | BACE2 | Q9Y5Z0 | 6/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9913167 | 1.00 | BACE1 (1.00) | BACE1KCNH2BACE2CYP2D6 | |
| SCHEMBL3300818 | 1.00 | BACE1 (1.00) | BACE1KCNH2BACE2CYP2D6 | |
| SCHEMBL12446779 | 0.89 | BACE1 (0.80) | BACE1KCNH2BACE2CYP2D6 | |
| SCHEMBL7924115 | 0.89 | BACE1 (0.80) | BACE1KCNH2BACE2CYP2D6 | |
| SCHEMBL2932760 | 0.87 | BACE1 (0.77) | BACE1KCNH2BACE2 | |
| SCHEMBL2620353 | 0.87 | BACE1 (0.77) | BACE1KCNH2BACE2 | |
| SCHEMBL2932765 | 0.87 | BACE1 (0.77) | BACE1KCNH2BACE2 | |
| SCHEMBL17174978 | 0.85 | BACE1 (1.00) | BACE1KCNH2BACE2 | |
| SCHEMBL3304263 | 0.85 | BACE1 (0.75) | BACE1KCNH2BACE2CYP2D6 | |
| SCHEMBL3304268 | 0.85 | BACE1 (0.75) | BACE1KCNH2BACE2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2332943-B1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2015-04-22 | — | — | EP | claimed |
| US-8198269-B2 | Fused aminodihydrothiazine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-12 | — | — | US | claimed |
| US-20100093999-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | claimed |
| EP-2332943-B1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2015-04-22 | — | — | EP | disclosed |
| US-8198269-B2 | Fused aminodihydrothiazine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20100093999-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093999-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | BACE1, BACE2, APP | BACE1 1/4885KCNH2 1984/4885BACE2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.